Analyst Ratings For Concert Pharmaceuticals Inc (NASDAQ:CNCE)
Today, Janney Montgomery Scott initiated coverage on Concert Pharmaceuticals Inc (NASDAQ:CNCE) with a Neutral.
There are 4 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Concert Pharmaceuticals Inc (NASDAQ:CNCE) is Buy with a consensus target price of $28.50 per share, a potential 102.56% upside.
Some recent analyst ratings include
- 9/13/2018-Concert Pharmaceuticals Inc (NASDAQ:CNCE) has coverage initiated with a Neutral rating
- 8/3/2018-Concert Pharmaceuticals Inc (NASDAQ:CNCE) had its Buy rating reiterated by HC Wainwright
- 8/2/2018-Concert Pharmaceuticals Inc (NASDAQ:CNCE) had its Buy rating reiterated by Mizuho with a $27.00 price target
- 1/12/2018-Concert Pharmaceuticals Inc (NASDAQ:CNCE) had its Buy rating reiterated by Stifel Nicolaus with a $27.00 price target
- 6/12/2017-Concert Pharmaceuticals Inc (NASDAQ:CNCE) had its Buy rating reiterated by Aegis with a $25.00 price target
Recent Insider Trading Activity For Concert Pharmaceuticals Inc (NASDAQ:CNCE)
Concert Pharmaceuticals Inc (NASDAQ:CNCE) has insider ownership of 9.40% and institutional ownership of 73.26%.
- On 7/10/2018 Nancy Stuart, COO, sold 31,418 with an average share price of $17.87 per share and the total transaction amounting to $561,439.66.
- On 4/17/2018 James V Cassella, Insider, sold 10,582 with an average share price of $20.18 per share and the total transaction amounting to $213,544.76.
- On 2/1/2018 Richard Aldrich, Director, sold 11,946 with an average share price of $20.89 per share and the total transaction amounting to $249,551.94.
- On 1/29/2018 Richard Aldrich, Director, sold 18,054 with an average share price of $20.63 per share and the total transaction amounting to $372,454.02.
- On 1/26/2018 Richard Aldrich, Director, sold 5,000 with an average share price of $20.46 per share and the total transaction amounting to $102,300.00.
- On 1/24/2018 Richard Aldrich, Director, sold 30,000 with an average share price of $19.68 per share and the total transaction amounting to $590,400.00.
- On 1/22/2018 Richard Aldrich, Director, sold 10,000 with an average share price of $19.55 per share and the total transaction amounting to $195,500.00.
About Concert Pharmaceuticals Inc (NASDAQ:CNCE)
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, which has completed the Phase 1 clinical trials for the treatment of patients with narcolepsy; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. The company is also developing CTP-692, a selective deuterium-modified analog of the endogenous amino acid, D-serine, which is in preclinical studies for use in the treatment of patients with schizophrenia. It has strategic collaborations with Celgene Pharmaceuticals, Inc.; Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.
Recent Trading Activity for Concert Pharmaceuticals Inc (NASDAQ:CNCE)
Shares of Concert Pharmaceuticals Inc closed the previous trading session at 14,07 −0,030 0,21 % with 14.4 shares trading hands.
